Skip to content
10-Q

Quarterly Report

Metagenomi Therapeutics, Inc. MGX

0000950170-25-070463

← back to feed
Filed
May 13, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2025 · May 7, 2025 37.38M sh
Current Liabilities Q1 2025 · Mar 31, 2025 $39.89M
Current Liabilities Q1 2025 · Dec 31, 2024 $37.31M
Total Liabilities Q1 2025 · Mar 31, 2025 $85.21M
Total Liabilities Q1 2025 · Dec 31, 2024 $89.74M
Current Assets Q1 2025 · Mar 31, 2025 $233.2M
Current Assets Q1 2025 · Dec 31, 2024 $257.96M
Total Assets Q1 2025 · Mar 31, 2025 $297.87M
Total Assets Q1 2025 · Dec 31, 2024 $324.6M
Cash And Equivalents Q1 2025 · Dec 31, 2024 $27.39M
Cash And Equivalents Q1 2025 · Mar 31, 2024 $102.56M
Shares Diluted Q1 2025 · Mar 31, 2024 21.14M sh
Capex Q1 2025 · Mar 31, 2024 $915K
Operating Cash Flow Q1 2025 · Mar 31, 2024 −$29.85M
Stockholders Equity Q1 2025 · Mar 31, 2024 $275.63M
Stockholders Equity Q1 2025 · Dec 31, 2023 −$135.58M
Eps Diluted Q1 2025 · Mar 31, 2024 −$1.19
Eps Basic Q1 2025 · Mar 31, 2024 −$1.19
Sga Expense Q1 2025 · Mar 31, 2024 $8.75M
Rd Expense Q1 2025 · Mar 31, 2024 $31.44M
Net Income Q1 2025 · Mar 31, 2024 −$25.15M
Operating Income Q1 2025 · Mar 31, 2024 −$29.03M
Revenue Q1 2025 · Mar 31, 2024 $11.16M